Bortezomib-induced congestive cardiac failure in a patient with multiple myeloma - PubMed (original) (raw)
Case Reports
Bortezomib-induced congestive cardiac failure in a patient with multiple myeloma
Ajay Gupta et al. Cardiovasc Toxicol. 2012 Jun.
Abstract
Bortezomib therapy is known to be associated with neurological side effects and thrombocytopenia. Its cardiac side effects are however not well known. The patient, a 70-year-old woman, with a previous history of myocardial infarction and subsequent coronary stenting, was detected to have multiple myeloma stage IIIa. She was started on Inj. Bortezomib (1.3 mg/m(2)) and Tab. Dexamethasone 40 mg on a weekly basis. She showed good response to therapy. Three days after administration of the 22nd dose of bortezomib, she presented to the hospital with congestive cardiac failure. Echocardiography revealed a drop in the left ventricular ejection fraction from pretreatment levels of 45-50 to 25%. Patient was treated medically for left ventricular failure secondary to a suspected ischemic etiology. Coronary angiography revealed non-critical coronary artery disease with patent right coronary artery and left circumflex stents. The N-terminal pro-brain natriuretic peptide (NT-proBNP) levels that were initially raised 4,030 pg/ml (<125 pg/ml) declined to 2,280 pg/ml a week later and subsequently normalized over the next 2 weeks. The patient responded well to treatment and was then discharged. The left ventricular ejection normalized over the next 3 months. Cardiac side effects of bortezomib are not well reported. Elderly patients and those with preexisting cardiac conditions could be at increased cardiovascular risk. Since this risk increases once a cumulative dose of 20 mg/m(2) has been administered, patients need to be monitored more intensively once this threshold has been attained. Increased awareness of these cardiac side effects is necessary for patients' safety.
Similar articles
- [Bortezomib-associated acute congestive heart failure in a patient with multiple myeloma].
Aota Y, Gotoh A, Hanyu N, Honma T, Morisaki M, Yokoyama T, Kitagawa N, Komatsu N. Aota Y, et al. Rinsho Ketsueki. 2015 Jan;56(1):44-7. doi: 10.11406/rinketsu.56.44. Rinsho Ketsueki. 2015. PMID: 25745969 Japanese. - Severe heart failure after bortezomib treatment in a patient with multiple myeloma: a case report and review of the literature.
Bockorny M, Chakravarty S, Schulman P, Bockorny B, Bona R. Bockorny M, et al. Acta Haematol. 2012;128(4):244-7. doi: 10.1159/000340050. Epub 2012 Sep 4. Acta Haematol. 2012. PMID: 22964848 Review. - Myocardial scarring following chemotherapy for multiple myeloma detected using late gadolinium hyperenhancement cardiovascular magnetic resonance.
Foley PW, Hamilton MS, Leyva F. Foley PW, et al. J Cardiovasc Med (Hagerstown). 2010 May;11(5):386-8. doi: 10.2459/JCM.0b013e32832f3ff2. J Cardiovasc Med (Hagerstown). 2010. PMID: 19584744 - Efficacy and safety of bortezomib plus dexamethasone therapy for refractory or relapsed multiple myeloma: once-weekly administration of bortezomib may reduce the incidence of gastrointestinal adverse events.
Fukushima T, Nakamura T, Iwao H, Nakajima A, Miki M, Sato T, Sakai T, Sawaki T, Fujita Y, Tanaka M, Masaki Y, Nakajima H, Motoo Y, Umehara H. Fukushima T, et al. Anticancer Res. 2011 Jun;31(6):2297-302. Anticancer Res. 2011. PMID: 21737655 - Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
Badros A, Goloubeva O, Dalal JS, Can I, Thompson J, Rapoport AP, Heyman M, Akpek G, Fenton RG. Badros A, et al. Cancer. 2007 Sep 1;110(5):1042-9. doi: 10.1002/cncr.22921. Cancer. 2007. PMID: 17654660 Review.
Cited by
- Cardiovascular-specific mortality among multiple myeloma patients: a population-based study.
Yin X, Fan F, Zhang B, Hu Y, Sun C. Yin X, et al. Ther Adv Hematol. 2022 Mar 31;13:20406207221086755. doi: 10.1177/20406207221086755. eCollection 2022. Ther Adv Hematol. 2022. PMID: 35387110 Free PMC article. - Bortezomib-Induced Reversible Cardiomyopathy: Recovered With Guideline-Directed Medical Therapy.
Sundaravel SH, Marar RI, Abbasi MA, Baljevic M, Stone JR. Sundaravel SH, et al. Cureus. 2021 Dec 9;13(12):e20295. doi: 10.7759/cureus.20295. eCollection 2021 Dec. Cureus. 2021. PMID: 35024253 Free PMC article. - Non-Hematologic Toxicity of Bortezomib in Multiple Myeloma: The Neuromuscular and Cardiovascular Adverse Effects.
Pancheri E, Guglielmi V, Wilczynski GM, Malatesta M, Tonin P, Tomelleri G, Nowis D, Vattemi G. Pancheri E, et al. Cancers (Basel). 2020 Sep 7;12(9):2540. doi: 10.3390/cancers12092540. Cancers (Basel). 2020. PMID: 32906684 Free PMC article. Review. - Renal and pulmonary thrombotic microangiopathy triggered by proteasome-inhibitor therapy in patient with smoldering myeloma: A renal biopsy and autopsy case report.
Cassol CA, Williams MPA, Caza TN, Rodriguez S. Cassol CA, et al. Medicine (Baltimore). 2019 Sep;98(39):e17148. doi: 10.1097/MD.0000000000017148. Medicine (Baltimore). 2019. PMID: 31574818 Free PMC article. - KPC1 alleviates hypoxia/reoxygenation-induced apoptosis in rat cardiomyocyte cells though BAX degradation.
Yuan Y, Wang YY, Liu X, Luo B, Zhang L, Zheng F, Li XY, Guo LY, Wang L, Jiang M, Pan YM, Yan YW, Yang JY, Chen SY, Wang JN, Tang JM. Yuan Y, et al. J Cell Physiol. 2019 Dec;234(12):22921-22934. doi: 10.1002/jcp.28854. Epub 2019 May 30. J Cell Physiol. 2019. PMID: 31148189 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials